CHANGES IN MBS BULK BILLING INCENTIVES ADDRESS GP CAPACITY IN WOMEN’S HEALTH Reforms expand professional pathways and clinical scope to meet the demands of patients
With
Dr Sneha Wadhwani, GP
Bondi Junction Medical & Dental Centre &
Conjoint Lecturer, UNSW Medical School &
Clinical Director NSW & ACT,
Head of GP Wellbeing & Women’s Health,
ForHealth Group &
Co-Founder & National Clinical Director
Evoca Women’s Health
SEGMENT
Filmed in Sydney | November 2025
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
These codes facilitate bulk billing for essential services such as menopause health assessments and long-acting reversible contraceptives, enabling more women to access critical care at little or no cost. These advancements address long-standing challenges faced by GPs, including time constraints and inadequate funding, which have historically limited comprehensive women’s health care delivery.
The investment in training for IUDs and contraceptive implants is another vital component of this initiative, equipping more GPs to provide these services effectively. Dr. Wadhwani notes that the Evoca model prioritises GP-led, holistic care, with trained practitioners working alongside allied health professionals to support women through various stages of their lives.
With the expansion of Evoca clinics from one to 43 nationally and an expectation that 75% will eventually adopt bulk billing, Dr Wadhwani believes there is a significant opportunity for GPs interested in women’s health to upskill and serve women who have previously delayed care due to costs. Dr. Wadhwani emphasises that addressing women’s health has far-reaching effects on families and communities, creating a compelling call to action for clinicians to embrace these new incentives.
Source: Adapted from transcript
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
-
Understanding extracellular vesicles in cancer therapy research
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
-
Strategic research investments for health and prosperity
The CEO of Research Australia, Nadia Levin spoke with Australian Health Journal about the following:
– Current medical research and development landscape in Australia
– Investment required to support the Health and Medical Research and Innovation pipeline
– The National Medical Products Industry Plan and its impact on the Australian economy
– The Health and Medical Research WorkforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
